Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: the OCEANS study

American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions
Richard H KarasMichael H Davidson

Abstract

High-dose HMG-CoA reductase inhibitors (statins) fail to prevent approximately two-thirds of cardiovascular events. This fact has focused increased attention on treating abnormalities of non-high-density lipoprotein-cholesterol (non-HDL-C), HDL-C, and triglycerides in national guidelines and has intensified interest in combination therapy. The OCEANS study (Open-label evaluation of the safety and efficacy of a Combination of niacin ER and simvAstatin in patieNts with dySlipidemia; ClinicalTrials.gov identifier: NCT00080275) evaluated the safety and efficacy of a combination of niacin extended release and simvastatin (NER/S; SIMCOR) over 52 weeks in 520 patients with mixed dyslipidemia. After a >or=4-week run-in phase of diet modification and simvastatin 40 mg/day, median baseline values (mg/dL) were: non-HDL-C = 141, low-density lipoprotein-cholesterol (LDL-C) = 110, HDL-C = 45, and triglyceride = 151. Patients were randomized to an 8- or 12-week niacin titration scheme to a maximum NER/S dosage of 2,000/40 mg/day. Differences between titration groups in tolerability, safety, and efficacy were minimal; therefore, all results are for pooled titration groups. The safety of NER/S was consistent with the safety profile of each indi...Continue Reading

References

Aug 8, 1990·JAMA : the Journal of the American Medical Association·A Garg, S M Grundy
Dec 28, 1999·JAMA : the Journal of the American Medical Association·J C LaRosaS Vupputuri
May 23, 2001·JAMA : the Journal of the American Medical Association·UNKNOWN Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
Jan 5, 2002·The New England Journal of Medicine·B G BrownJ J Albers
Sep 21, 2002·Lancet·Duncan M Geddes
Dec 28, 2002·Diabetes Care·Stanley H Hsia
Jul 28, 2004·The American Journal of Cardiology·Melvyn Rubenfire, UNKNOWN Impact of Medical Subspecialty on Patient Compliance to Treatment Study Group
Aug 22, 2006·Expert Review of Cardiovascular Therapy·Jennifer G Robinson, Michael H Davidson
Nov 2, 2006·Current Medical Research and Opinion·Allen J TaylorLance E Sullenberger

❮ Previous
Next ❯

Citations

Mar 19, 2011·Cardiovascular Drugs and Therapy·Christie M BallantyneJames C Stolzenbach
Nov 26, 2010·Current Atherosclerosis Reports·Carlos A DujovneMatthew K Ito
Nov 1, 2011·Current Atherosclerosis Reports·Todd C VillinesAllen J Taylor
Aug 21, 2009·International Journal of Clinical Practice·V S KamannaM L Kashyap
Nov 26, 2010·International Journal of Clinical Practice·T A Jacobson
Oct 9, 2009·Vascular Health and Risk Management·Rakesh K SharmaHanumanth K Reddy
May 13, 2014·Molecular Aspects of Medicine·Huifen WangAlice H Lichtenstein
Jun 6, 2009·QJM : Monthly Journal of the Association of Physicians·M Miller
Oct 28, 2008·Current Cardiology Reports·Peter P Toth
Feb 10, 2010·Expert Opinion on Investigational Drugs·Kai-Hang YiuHung-Fat Tse
Mar 23, 2011·Expert Opinion on Drug Safety·Michel Farnier
Jun 24, 2010·Expert Opinion on Pharmacotherapy·Erica L BrooksRichard H Karas
Aug 14, 2008·Current Medical Research and Opinion·Jonathan BelseyNigel Hague
Mar 11, 2015·Scientific Reports·Linlin MaJie Zheng
Oct 22, 2008·Expert Opinion on Pharmacotherapy·Karam Kostner, Soneil Gupta
May 4, 2012·Journal of Pharmacy Practice·Jennifer SanteeHeather Pace
Feb 1, 2012·Therapeutic Advances in Drug Safety·Clement K M Ho, Simon W Walker
Jun 16, 2017·The Cochrane Database of Systematic Reviews·Stefan SchandelmaierAlain J Nordmann
Feb 21, 2009·Nature Clinical Practice. Endocrinology & Metabolism·Arshag D Mooradian
Mar 29, 2014·Arteriosclerosis, Thrombosis, and Vascular Biology·Linlin MaJie Zheng
Jul 4, 2009·Current Opinion in Cardiology·Derek J Hausenloy, Derek M Yellon
Aug 18, 2009·Fundamental & Clinical Pharmacology·Zeljko Reiner
Feb 2, 2019·Current Pharmaceutical Design·Michele ScognamiglioClaudio Napoli
Apr 1, 2009·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Roopal B ThakkarRobert J Padley
Oct 4, 2008·International Journal of Immunopathology and Pharmacology·D KalogeromitrosT C Theoharides
Nov 21, 2008·Expert Review of Cardiovascular Therapy·Anthony N Vo, Moti L Kashyap

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.